Investment Thesis

.

Competitive Moat

Moderna possesses a strong intangible asset moat, bolstered by its proprietary mRNA technology platform that has proven highly effective and scalable. The company's first-mover advantage in mRNA vaccines, particularly during the COVID-19 pandemic, has established substantial brand recognition and regulatory credibility. However, competitive threats from established pharmaceutical companies like Pfizer and newer entrants developing mRNA and alternative vaccine technologies could erode market share. Despite these threats, the durability of Moderna's advantage is expected to remain solid over the next 5-10 years, given the complexity and regulatory hurdles associated with vaccine development.

Growth Engine

The future revenue growth for Moderna is primarily driven by its expanding total addressable market (TAM), estimated at over $100 billion when considering both infectious diseases and oncology. New product lines such as personalized cancer vaccines and RSV vaccines are set to contribute meaningfully to revenue streams. The company is gaining market share in the oncology space, which is projected to be a game-changer. Organic growth is anticipated to significantly outpace acquisition-driven growth, as Moderna continues to innovate within its existing framework.